[HTML][HTML] C-reactive protein and implications in rheumatoid arthritis and associated comorbidities
JE Pope, EH Choy - Seminars in arthritis and rheumatism, 2021 - Elsevier
C-reactive protein (CRP) is routinely assessed as a marker of systemic inflammation in
rheumatoid arthritis (RA). However, it is also an immune regulator that plays an important …
rheumatoid arthritis (RA). However, it is also an immune regulator that plays an important …
Adverse effects of biologics: a network meta‐analysis and Cochrane overview
Background Biologics are used for the treatment of rheumatoid arthritis and many other
conditions. While the efficacy of biologics has been established, there is uncertainty …
conditions. While the efficacy of biologics has been established, there is uncertainty …
A structured literature review of the burden of illness and unmet needs in patients with rheumatoid arthritis: a current perspective
PC Taylor, A Moore, R Vasilescu, J Alvir… - Rheumatology …, 2016 - Springer
While rheumatologists often focus on treatment targets, for many patients with rheumatoid
arthritis (RA), control over pain and fatigue, as well as sustaining physical function and …
arthritis (RA), control over pain and fatigue, as well as sustaining physical function and …
[PDF][PDF] Adult measures of general health and health‐related quality of life: Medical outcomes study short form 36‐item (SF‐36) and short form 12‐item (SF‐12) health …
The aim of this review is to provide a summary of adult measures of general health and
health-related quality of life (HRQOL) commonly used in rheumatology research studies …
health-related quality of life (HRQOL) commonly used in rheumatology research studies …
Quality of life in psoriatic arthritis
T Gudu, L Gossec - Expert review of clinical immunology, 2018 - Taylor & Francis
ABSTRACT Introduction: Psoriatic arthritis (PsA) is a multi-organ chronic inflammatory
disease which impacts patients both physically and psychologically. The highest priority for …
disease which impacts patients both physically and psychologically. The highest priority for …
Biological therapies in immune-mediated inflammatory diseases: can biosimilars reduce access inequities?
DC Baumgart, L Misery, S Naeyaert… - Frontiers in …, 2019 - frontiersin.org
Biological therapies are an effective treatment for a range of immune-mediated inflammatory
diseases (IMIDs), including rheumatoid arthritis, psoriasis, and inflammatory bowel …
diseases (IMIDs), including rheumatoid arthritis, psoriasis, and inflammatory bowel …
Call for action: how to improve use of patient-reported outcomes to guide clinical decision making in rheumatoid arthritis
Current guidelines for the management of rheumatoid arthritis (RA) recommend early
treatment and a treat-to-target goal of remission or low disease activity. Over the past …
treatment and a treat-to-target goal of remission or low disease activity. Over the past …
Burden of disease in treated rheumatoid arthritis patients: going beyond the joint
Objective The disease burden in rheumatoid arthritis (RA) extends beyond the joint. This
article evaluates the physical and psychosocial extra-articular burden of treated RA and …
article evaluates the physical and psychosocial extra-articular burden of treated RA and …
Selective increase of cerebrospinal fluid IL-6 during experimental systemic inflammation in humans: association with depressive symptoms
H Engler, P Brendt, J Wischermann, A Wegner… - Molecular …, 2017 - nature.com
Systemic inflammation is accompanied by profound behavioral and mood changes that
resemble symptoms of depression. Findings in animals suggest that pro-inflammatory …
resemble symptoms of depression. Findings in animals suggest that pro-inflammatory …
[HTML][HTML] Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM …
EC Keystone, PC Taylor, Y Tanaka, C Gaich… - Annals of the …, 2017 - ard.bmj.com
Background To assess the effect of baricitinib on patient-reported outcomes (PROs) in
patients with active rheumatoid arthritis and an inadequate response to methotrexate (MTX) …
patients with active rheumatoid arthritis and an inadequate response to methotrexate (MTX) …